Metastases, Neoplasm Clinical Trial
Official title:
Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases
Verified date | January 2018 |
Source | Maastricht Radiation Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.
Status | Completed |
Enrollment | 155 |
Est. completion date | September 4, 2014 |
Est. primary completion date | September 4, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Cerebral metastasized patients Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastro Clinic | Maastricht |
Lead Sponsor | Collaborator |
---|---|
Maastricht Radiation Oncology |
Netherlands,
Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P. Decoding tumour phenotype by noninvasive imag — View Citation
Rodrigues G, Zindler J, Warner A, Lagerwaard F. Recursive partitioning analysis for the prediction of stereotactic radiosurgery brain metastases lesion control. Oncologist. 2013;18(3):330-5. doi: 10.1634/theoncologist.2012-0316. Epub 2013 Feb 19. — View Citation
Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ, Lagerwaard FJ. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 2013 Mar;106(3):370-4. doi: 10.1016/j. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Area under the curve of published prognostic scores | Area under the curve published prognostic scores | 1 year | |
Other | Mismatch rate of published prognostic scores | Mismatch rate of published prognostic scores | 1 year | |
Primary | Sensitive value of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics | Sensitivity of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. | 1 year | |
Primary | Sensitive value of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics | Sensitivity of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. | 1 year | |
Secondary | Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics. | Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics. | 1 year | |
Secondary | Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics. | Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics. | 1 year | |
Secondary | Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics. | Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00065117 -
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
|
Phase 2 | |
Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
Terminated |
NCT00048893 -
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00037869 -
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
|
Phase 3 | |
Completed |
NCT00034918 -
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT01115751 -
A Study in Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT01115803 -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
|
Phase 1 | |
Completed |
NCT00056173 -
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05419518 -
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
|
Phase 2 | |
Terminated |
NCT00034697 -
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
|
Phase 2 | |
Completed |
NCT00055471 -
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT00046514 -
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00046527 -
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT00041808 -
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
|
Phase 1/Phase 2 | |
Completed |
NCT00037609 -
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00038038 -
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
|
N/A | |
Completed |
NCT03670992 -
Surgical Treatment of Pancreatic RCC Metastases
|
||
Terminated |
NCT00050336 -
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
|
Phase 3 | |
Recruiting |
NCT03563326 -
Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
|
Phase 1 | |
Completed |
NCT00044863 -
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
|
Phase 2 |